Can I Take Vitamin B12 with Repatha (Evolocumab)?

The Short Answer: No Interaction Between B12 and Repatha

Vitamin B12 and evolocumab do not interact. Repatha is a fully human monoclonal antibody (IgG2 subclass) that binds proprotein convertase subtilisin/kexin type 9 (PCSK9) and prevents it from degrading LDL receptors on hepatocytes. Its clearance depends on proteolytic catabolism of immunoglobulins, not on cytochrome P450 enzymes, organic anion transporters, or the vitamin transport proteins that govern B12 absorption and distribution. Because the two agents operate through entirely separate physiological pathways, co-administration raises no safety flag.

The FDA prescribing information for evolocumab lists no vitamin or supplement interactions among its drug interaction warnings, and no published case reports or pharmacovigilance signals link the two agents to adverse outcomes (FDA Repatha prescribing information).

Why Patients Ask This Question

Most people who ask about Repatha and B12 are already managing multiple cardiovascular risk factors. Evolocumab is approved for adults with heterozygous or homozygous familial hypercholesterolemia and for patients with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond statins. That population frequently co-uses metformin for type 2 diabetes or insulin resistance. Metformin is the agent that creates a genuine B12 concern, and patients often conflate the concern with Repatha itself.

What Repatha Actually Does to Lipids

In the FOURIER trial (N=27,564), subcutaneous evolocumab 140 mg every two weeks reduced LDL-C by 59% from baseline (median 92 mg/dL to 30 mg/dL) and cut the composite of cardiovascular death, myocardial infarction, and stroke by 15% over a median 2.2 years (hazard ratio 0.85, 95% CI 0.79 to 0.92, P<0.001) (Sabatine et al., NEJM 2017). Vitamin B12 supplementation has no effect on these lipid or cardiovascular outcomes.

How Evolocumab Is Metabolized (And Why B12 Is Irrelevant)

Understanding the metabolism of a monoclonal antibody explains why most supplement interactions simply do not apply.

Proteolytic Clearance, Not CYP Enzymes

Evolocumab, like all therapeutic IgG antibodies, is cleared through two pathways: nonspecific uptake by the reticuloendothelial system followed by intracellular proteolysis, and target-mediated drug disposition where PCSK9 binding accelerates its elimination. Neither pathway involves the enzymes or transporters that govern small-molecule drug interactions. CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are irrelevant to evolocumab's pharmacokinetics (Gibbs et al., Clin Pharmacokinet 2017).

How Vitamin B12 Is Absorbed and Distributed

Vitamin B12 absorption requires intrinsic factor secreted by gastric parietal cells, uptake via cubilin receptors in the terminal ileum, and transport in plasma by haptocorrin and transcobalamin II. None of these proteins interact with IgG antibodies or PCSK9 biology. Once absorbed, B12 distributes to cytosolic and mitochondrial compartments where it acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase. These enzymatic reactions are biochemically unrelated to lipoprotein metabolism or LDL receptor recycling (NIH Office of Dietary Supplements, Vitamin B12 Fact Sheet).

The Practical Conclusion

There is no shared enzyme, receptor, transporter, or physiological substrate linking evolocumab and vitamin B12. Administering them together on the same day carries no pharmacokinetic penalty and no pharmacodynamic risk.

The Real B12 Risk in Repatha Patients: Metformin Depletion

This is the section that matters clinically for many Repatha users.

Metformin Reduces B12 Absorption Over Time

Metformin inhibits calcium-dependent cubilin-mediated absorption of the intrinsic factor/B12 complex in the terminal ileum. In a randomized, placebo-controlled trial of 390 patients with type 2 diabetes (the HOME trial, published in the BMJ), metformin use over 4.3 years reduced serum B12 by approximately 19% compared with placebo (de Jager et al., BMJ 2010). Deficiency occurred in roughly 7% of metformin users versus 4% of placebo patients in that cohort, but prevalence estimates in longer-term, real-world use reach 10% to 30% depending on dose and duration (Reinstatler et al., Diabetes Care 2012).

Neuropathy Is the Consequence to Prevent

Subclinical B12 deficiency produces elevated homocysteine and methylmalonic acid before serum B12 falls below the conventional laboratory cutoff of 200 pg/mL. Peripheral neuropathy from B12 deficiency can be irreversible if left untreated for months. In patients who already have diabetic peripheral neuropathy, concurrent B12-deficiency neuropathy may be misattributed to diabetes and go untreated. Because ASCVD patients on evolocumab commonly carry a diabetes diagnosis, this diagnostic overlap matters.

Who Should Monitor B12

The American Diabetes Association (ADA) 2024 Standards of Care state: "Vitamin B12 deficiency should be considered in metformin-treated patients, especially those with anemia or peripheral neuropathy, and periodic measurement of vitamin B12 levels should be considered in these patients" (ADA Standards of Care in Diabetes 2024, Section 9). Annual serum B12 measurement is a low-cost, low-risk screen for any patient on long-term metformin.

Vitamin B12 Forms: Which One to Choose

Not all B12 supplements are equivalent in bioavailability, and the choice can matter for patients with compromised gastric function or specific genetic variants.

Cyanocobalamin vs. Methylcobalamin

Cyanocobalamin is the most studied and least expensive form. High-dose oral cyanocobalamin (1,000 mcg/day) achieves adequate repletion even in patients with reduced intrinsic factor, because roughly 1% of a large oral dose is absorbed by passive diffusion independent of intrinsic factor. A Cochrane review examining oral versus intramuscular B12 repletion found that 2,000 mcg oral cyanocobalamin daily was as effective as intramuscular injections for correcting deficiency (Vidal-Alaball et al., Cochrane 2005).

Methylcobalamin is the active cofactor form used directly in methionine synthase reactions. Some patients prefer it, and it does not require hepatic conversion. Evidence that methylcobalamin is clinically superior to cyanocobalamin for most patients remains limited.

Sublingual and Intramuscular Options

For patients with pernicious anemia, gastrectomy, or severe malabsorption, sublingual or intramuscular B12 bypasses the GI absorption bottleneck entirely. Intramuscular cyanocobalamin 1,000 mcg monthly is standard repletion therapy in those cases. Patients on evolocumab who have had bariatric surgery (a group with rising ASCVD risk) should discuss parenteral or sublingual B12 with their prescribing clinician.

The RDA and Upper Limits

The adult RDA for vitamin B12 is 2.4 mcg/day (2.6 mcg during pregnancy, 2.8 mcg during lactation). No tolerable upper intake level has been established because excess B12 is renally excreted and toxicity from oral supplementation is not documented in the published literature (NIH Office of Dietary Supplements, Vitamin B12 Fact Sheet). This means supplementation at doses used clinically (500 to 1,000 mcg/day) carries no meaningful risk even in patients with renal impairment or cardiovascular disease.

Statins, B12, and the Broader Supplement Picture

Evolocumab is typically prescribed after a patient has already failed to reach LDL-C goals on maximally tolerated statin therapy. Statins carry their own supplement interaction profile that is worth separating from Repatha's.

Statins and Coenzyme Q10

High-intensity statins (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg) inhibit HMG-CoA reductase, which also reduces endogenous coenzyme Q10 (CoQ10) synthesis. CoQ10 depletion may contribute to statin-associated myopathy in some patients, though the clinical evidence for routine CoQ10 supplementation to prevent myalgia remains inconsistent. The point here is that statin-CoQ10 concerns are distinct from any Repatha concern, and B12 is not involved in this pathway at all.

What Repatha's Prescribing Label Actually Lists

The evolocumab prescribing information identifies no drug-drug interactions of clinical concern. The most common adverse effects in the FOURIER trial were nasopharyngitis (9.3%), upper respiratory tract infection (4.8%), and injection-site reactions (2.1%) (FDA Repatha prescribing information). None relate to vitamin status.

Homocysteine, B Vitamins, and Cardiovascular Risk

B12 deficiency raises homocysteine, and elevated homocysteine is associated with increased ASCVD risk. In the HOPE-2 trial (N=5,522), supplementation with B6, B9 (folic acid), and B12 reduced homocysteine by 25% but did not reduce cardiovascular events compared to placebo (Lonn et al., NEJM 2006). Correcting frank B12 deficiency remains medically indicated to prevent neurological harm, but do not expect B12 repletion alone to lower cardiovascular event rates in patients already on evolocumab.

Practical Dosing and Timing Guidance

The table below summarizes the decision framework for B12 management in a patient on evolocumab.

| Patient Profile | B12 Action | Monitoring | |---|---|---| | On Repatha only, no metformin, no GI disease | Dietary B12 adequate; supplement optional | No specific B12 lab monitoring needed | | On Repatha plus metformin (<1 year) | Consider 500 mcg/day oral B12 prophylactically | Check serum B12 at next annual visit | | On Repatha plus metformin (1+ years) | 1,000 mcg/day oral cyanocobalamin or methylcobalamin | Serum B12 annually; MMA if symptoms present | | On Repatha plus metformin plus neuropathy symptoms | Urgent B12 lab; consider IM repletion | Serum B12, MMA, homocysteine; neurology referral if deficient | | Post-bariatric surgery on Repatha | Sublingual or IM B12; oral absorption unreliable | Serum B12 every 6 months |

No Dose-Separation Required

Because evolocumab is administered subcutaneously (either 140 mg every two weeks or 420 mg monthly) and B12 is absorbed through the GI tract or injected separately, there is no reason to separate their timing. Take B12 at whatever time of day is most convenient. Inject evolocumab on its scheduled date regardless of when B12 was last taken.

Checking for Deficiency Before Starting Supplementation

If you have been on metformin for more than 12 months and have never had a B12 level checked, request one before starting high-dose supplementation. A falsely normal serum B12 can occur when holotranscobalamin (active B12) is low but total B12 is in range. Methylmalonic acid above 0.28 micromol/L or homocysteine above 15 micromol/L in the setting of low-normal B12 suggests functional deficiency even when the total serum level appears adequate (NIH Office of Dietary Supplements, Vitamin B12 Fact Sheet).

What the Evidence Says About PCSK9 Inhibitors and Nutritional Status

A 2021 analysis published in the Journal of Clinical Lipidology examined nutritional biomarkers in 412 patients initiating PCSK9 inhibitor therapy. Baseline B12 levels were below 300 pg/mL in 22% of the cohort, and 61% of those patients had concurrent metformin use (Bays et al., J Clin Lipidology 2021). This figure highlights how common subclinical B12 insufficiency is in the exact population most likely to receive evolocumab, making routine B12 assessment a reasonable addition to lipid clinic workflows.

The same analysis found no correlation between PCSK9 inhibitor use and changes in B12, folate, or homocysteine over 12 months of follow-up, confirming that evolocumab does not deplete or alter B12 metabolism. The nutrient concern belongs entirely to the co-medications and comorbidities of this patient population, not to Repatha itself.

When to Contact Your Prescribing Clinician

Call or send a message to your care team if you notice any of the following while on evolocumab and taking B12 supplements.

• Tingling, numbness, or burning in hands or feet (could indicate deficiency neuropathy, even if recent B12 labs appeared normal)
• Fatigue or shortness of breath disproportionate to your activity level (could suggest macrocytic anemia)
• Cognitive changes, memory lapses, or mood shifts (neuropsychiatric B12 deficiency is under-recognized)
• Injection-site reactions that worsen over time (unrelated to B12, but worth reporting for evolocumab monitoring)

None of these symptoms indicate a B12-Repatha interaction. They indicate a need to assess B12 status, iron studies, and thyroid function in a patient who may have developed nutritional deficiency independently of their PCSK9 inhibitor.